Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


C&C Vision: Small Company, Big Vision

This article was originally published in Start Up

Executive Summary

Presbyopia, the inability to focus close-up that come with aging, represents a blockbuster market opportunity since virtually everyone eventually suffers from the condition. The success of LASIK (laser surgery for vision correction) has created a demand on the part of patients and physicians for an alternative to glasses for the middle aged. C&C Vision hopes to be the first to offer a surgical treatment for presbyopia. Like others going after the market, however, C&C aims to validate its technology by addressing a medical need first: it is initially targeting cataracts. In doing so, however, it faces the risk of sidling up to, rather than directly attacking, the presbyopia market upon which it desires to be valued.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts